Cargando…

Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons

Biologic therapies have become central to the long-term management of many chronic diseases, including inflammatory rheumatic diseases. Over recent years, the development and licensing pathways for biosimilars have become more standardized, and several biosimilars have been made available for patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhlig, Till, Goll, Guro L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5850213/
https://www.ncbi.nlm.nih.gov/pubmed/28903542
http://dx.doi.org/10.1093/rheumatology/kex276